| Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044) |
|---|
| 04/25/2006 | US7033608 Method of making to form a core of polypeptide or other biologically active agent encapsulated in a matrix of poly(lactide/glycolide) copolymer as a blend of uncapped and end-capped forms |
| 04/25/2006 | US7033607 Gene therapy; complexing nucleic acid and polymer |
| 04/25/2006 | US7033606 Pharmaceutical composition intended in particular for the prevention and the treatment of radiomucositis and chemomucositis |
| 04/25/2006 | US7033605 performing an ocular transplant procedure; implanting in the eye a biodegradable drug delivery system containing an immunosuppressive agent and a bioerodible polymer. |
| 04/25/2006 | US7033603 Tissue engineering; drug delivery; fiber with hollow bore |
| 04/25/2006 | US7033600 Inverse latex and use in cosmetics |
| 04/25/2006 | US7033599 Injectable compositions for the controlled delivery of pharmacologically active compound |
| 04/25/2006 | US7033598 Methods and apparatus for enhanced and controlled delivery of a biologically active agent into the central nervous system of a mammal |
| 04/25/2006 | US7033591 use of a membrane fraction of gram-negative bacteria such as Klebsiella pnemoniae comprising proteoglycans in combination with anticancer treatment for immunostimulant and/or inducing an antitumor immune response in mammals including humans |
| 04/25/2006 | US7033588 combination of coenzyme Q and a surfactant can prevent ascites even when administering in a small dose and within a short period of time |
| 04/25/2006 | US7033582 Use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders |
| 04/25/2006 | US7033578 Antimycotic nail varnish composition |
| 04/25/2006 | US7033575 Delivery of physiologically active compounds through an inhalation route |
| 04/25/2006 | US7033574 Stable microbubbles suspensions injectable into living organisms |
| 04/25/2006 | US7033571 Multiple stimulus reversible hydrogels |
| 04/25/2006 | US7032601 Encapsulated materials |
| 04/25/2006 | CA2471821C Microcapsules having multiple shells and method for the preparation thereof |
| 04/25/2006 | CA2438097C Cannabinoids pharmaceutical formulations |
| 04/25/2006 | CA2433035C Pharmaceutical compositions comprising amlodipine maleate |
| 04/25/2006 | CA2265766C Rapidly disintegrating pellets |
| 04/25/2006 | CA2264687C Permeation enhancers for transdermal drug delivery compositions, devices, and methods |
| 04/25/2006 | CA2251949C Use of lofexidine in the manufacture of a medicament for treating attention deficit hyperactive disorder |
| 04/25/2006 | CA2250397C Improvements in or relating to encapsulation |
| 04/25/2006 | CA2141039C Surfactant free aerosol formulations containing beclomethasone dipropionate |
| 04/25/2006 | CA2126929C Non-reducing oligosaccharide and its production and use |
| 04/20/2006 | WO2006042336A2 Removal of impurities with supercritical fluids from ocular drug delivery devices during manufacturing |
| 04/20/2006 | WO2006042324A2 Antifungal composition applicable to body tissue, preferably nails |
| 04/20/2006 | WO2006042310A1 Biocompatible protein particles, particle devices and methods thereof |
| 04/20/2006 | WO2006042277A2 Extended release compositions of proton pump inhibitors |
| 04/20/2006 | WO2006042270A1 Method of inserion of a lipid-linked moiety into a pre-formed lipid assembly using microwaves |
| 04/20/2006 | WO2006042135A2 Flavored gelatin capsule and method of producing said capsule |
| 04/20/2006 | WO2006041967A1 Method of formation of the shape-retentive aggregates of gel particles and their uses |
| 04/20/2006 | WO2006041911A2 Device transdermal administration of drugs including acrylic polymers |
| 04/20/2006 | WO2006041908A2 Transdermal delivery of estradiol |
| 04/20/2006 | WO2006041907A2 Transdermal delivery of estradiol |
| 04/20/2006 | WO2006041878A2 Primary examiner |
| 04/20/2006 | WO2006041843A2 Pharmaceutical dosage form comprising meloxicam |
| 04/20/2006 | WO2006041764A1 Method of providing lubricious surfaces |
| 04/20/2006 | WO2006041613A2 Nanoparticles for targeting hepatoma cells |
| 04/20/2006 | WO2006041592A2 Large-scale manufacturing process for the production of pharmaceutical compositions |
| 04/20/2006 | WO2006041538A2 A mixture for transdermal delivery of low and high molecular weight compounds |
| 04/20/2006 | WO2006041521A1 Process for the formation of particulate material |
| 04/20/2006 | WO2006041409A1 Medical solution, method for producing and use thereof |
| 04/20/2006 | WO2006041192A1 Medicinal compositions containing apoptosis inducer |
| 04/20/2006 | WO2006041173A1 Enteric nutritional supplement |
| 04/20/2006 | WO2006041158A1 Method for modifying the ambience, and spray liquid and sprayer used in the method |
| 04/20/2006 | WO2006040680A1 Compositions and methods for intranasal, buccal, sublingual and pulmonary delivery of varenicline |
| 04/20/2006 | WO2006040598A2 Process for the preparation of suspension aerosol formulations, wherein the particles are formed by precipitation inside an aerosol canister |
| 04/20/2006 | WO2006040596A2 Compositions for intranasal administration |
| 04/20/2006 | WO2006040324A1 Composition containing omega-3 fatty acids and omega-6 fatty acids |
| 04/20/2006 | WO2006040196A1 4-hydroxy tamoxifen gel formulations |
| 04/20/2006 | WO2006040141A2 Segmented device for the delayed release of molecules in a tangential direction through thin films and uses thereof |
| 04/20/2006 | WO2006040112A2 Taste-masking pharmaceutical compositions |
| 04/20/2006 | WO2006029407A3 Method of preparing polymeric adhesive compositions utilizing the mechanism of interaction between the polymer components |
| 04/20/2006 | WO2006021762A3 Bi-layered oral healthcare composition for pouch-like devices |
| 04/20/2006 | WO2006012500A3 Crystallization of antibodies or fragments thereof |
| 04/20/2006 | WO2006007351A3 Squeeze controlled oral dosage form |
| 04/20/2006 | WO2006005017A3 Oral composition comprising carbamylating agent |
| 04/20/2006 | WO2005120605A3 Flow regulator |
| 04/20/2006 | WO2005112984A3 Apparatus and method for transdermal delivery of parathyroid hormone agents |
| 04/20/2006 | WO2005110361A3 Nucleotide-cochleate compositions and methods of use |
| 04/20/2006 | WO2005107811A3 Drug delivery device |
| 04/20/2006 | WO2005094893A3 Freeze-dried, free-flowing, particulate composition having improved palatability |
| 04/20/2006 | WO2005074912A3 Antiparasitic composition containing an organic amine salt of closantel |
| 04/20/2006 | WO2005072709A3 Formulations for poorly soluble drugs |
| 04/20/2006 | WO2005063218A3 Pharmaceutical formulations of bisphosphonates |
| 04/20/2006 | WO2005051489A3 Fast dissolving solid oral dosage forms of galanthamine |
| 04/20/2006 | WO2005051322A3 Controlled release pharmaceutical formulations comprising carvedilol, free based and its salts |
| 04/20/2006 | WO2005042051A3 Method for transdermal delivery of permeant substances |
| 04/20/2006 | WO2005041941A3 Valsartan containing formulation |
| 04/20/2006 | WO2004108088A3 Methods and compositions for interferon therapy |
| 04/20/2006 | WO2004071420A3 Compositions and methods for less immunogenic protein formulations |
| 04/20/2006 | US20060084950 Controlled ocular lens regeneration |
| 04/20/2006 | US20060084943 Implant delivery catheter system and methods for its use |
| 04/20/2006 | US20060084942 Tapered hollow metallic microneedle array assembly and method of making and using the same |
| 04/20/2006 | US20060084797 High affinity TGFbeta nucleic acid ligands and inhibitors |
| 04/20/2006 | US20060084704 Methods and compositions for enhancing degradation of nuclear receptor transcription factors and uses thereof |
| 04/20/2006 | US20060084703 Injectable liquid formulation of paracetamol |
| 04/20/2006 | US20060084685 Ophthalmological use of roflumilast for the treatment of diseases of the eye |
| 04/20/2006 | US20060084684 Topically applicable pharmaceutical preparation |
| 04/20/2006 | US20060084633 Formulations for treating or preventing mucositis |
| 04/20/2006 | US20060084617 Methods for delivery of nucleic acids |
| 04/20/2006 | US20060084602 Platelet-derived growth factor compositions and methods of use thereof |
| 04/20/2006 | US20060084149 Forming complex in which single-stranded nucleic acid is bound to a double-stranded beta -1,3-glucan which as 1,6-glucopyranoside branch and is chemically modified through periodate oxidation and reductive amination so as to impart nucleic acid-binding functional groups; for use as an antisense agent |
| 04/20/2006 | US20060083879 Surface modification process |
| 04/20/2006 | US20060083792 Utilizing nanocrystalline silver metal, alloy or compound for localized tissue infections; reducing side effects; limiting overuse of antibiotics |
| 04/20/2006 | US20060083790 Combination of an ibat inhibitor and a metal salt for the treatment of diarrhoea |
| 04/20/2006 | US20060083786 Taste masking pharmaceutical composition containing levocetirizine |
| 04/20/2006 | US20060083785 Large dose ribavirin formulations |
| 04/20/2006 | US20060083784 Amorphous pharmaceutical compositions |
| 04/20/2006 | US20060083783 Treating metabolic syndrome with fenofibrate |
| 04/20/2006 | US20060083782 Methods and compositions useful for administration of chemotherapeutic agents |
| 04/20/2006 | US20060083781 Functionalized solid lipid nanoparticles and methods of making and using same |
| 04/20/2006 | US20060083780 liposomes; nucleic acid lipid particles; gene therapy; improved membrane fluidity |
| 04/20/2006 | US20060083778 Controlled release compositions of estradiol metabolites |
| 04/20/2006 | US20060083777 Providing localized antimicrobial and antiinflammatory effect; utilizing crystalline silver metal, alloy or compound |
| 04/20/2006 | US20060083759 Stabilization of the profile of release of active substances from a formulation |
| 04/20/2006 | US20060083743 Method of cancer therapy by in situ production of F5 antibodies |
| 04/20/2006 | US20060083733 High-concentration preparation of soluble thrombomodulin |
| 04/20/2006 | US20060083717 System and method for forming a non-ablative cardiac conduction block |